文献速递结核与非结核分枝杆菌艾滋病与性传播感染

南非孕妇耐多药/利福平耐药结核治疗后的母婴结局

Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究回顾性分析了南非KwaZulu-Natal省King Dinuzulu医院2013年1月1日至2017年12月31日期间开始治疗耐多药/利福平耐药结核的108名孕妇,其中88人(81%)合并HIV感染。67%的孕妇获得了良好的结核治疗结局,但48%的孕妇出现不良妊娠结局;在12月龄评估的86名儿童中,84%结局良好。

要点

  • 孕妇耐多药/利福平耐药结核治疗结局与非孕妇相当。
  • 贝达喹啉和左氧氟沙星独立关联低出生体重风险增加。
  • 暴露于贝达喹啉的婴儿在1岁时超过80%体重增长和发育正常。

核心结论

  • 孕妇耐多药/利福平耐药结核治疗结局与非孕妇相当。
  • 暴露于贝达喹啉的婴儿低出生体重比例更高,但1岁时超过80%体重增长和发育正常。

研究设计与样本

  • 回顾性记录审查,纳入南非King Dinuzulu医院2013年1月1日至2017年12月31日开始治疗耐多药/利福平耐药结核的108名孕妇,并进行婴儿临床评估。

主要发现

  • 108名孕妇中88名(81%)合并HIV感染;72名(67%)获得良好结核治疗结局。
  • 多因素分析中贝达喹啉和左氧氟沙星均独立关联低出生体重风险增加;86名12月龄评估儿童中72名(84%)结局良好。

临床怎么用

  • 对孕妇使用贝达喹啉和左氧氟沙星方案时需关注低出生体重风险,并加强婴儿生长监测。
  • 贝达喹啉暴露婴儿1岁内多数发育正常,支持在必要情况下继续使用该药。

局限性

  • 回顾性记录审查设计,可能存在信息偏倚。
  • 样本量有限(108名孕妇),婴儿评估仅86名完成12月龄随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on safety and efficacy of second-line tuberculosis drugs in pregnant women and their infants are severely limited due to exclusion from clinical trials and expanded access programs. METHODS: Pregnant women starting treatment for multidrug/rifampicin-resistant (MDR/RR)-tuberculosis at King Dinuzulu Hospital in KwaZulu-Natal, South Africa, from 1 January 2013 to 31 December 2017, were included. We conducted a record review to describe maternal treatment and pregnancy outcomes, and a clinical assessment to describe infant outcomes. RESULTS: Of 108 pregnant women treated for MDR/RR-tuberculosis, 88 (81%) were living with human immunodeficiency virus.. Favorable MDR/RR-tuberculosis treatment outcomes were reported in 72 (67%) women. Ninety-nine (91%) of the 109 babies were born alive, but overall, 52 (48%) women had unfavorable pregnancy outcomes. Fifty-eight (54%) women received bedaquiline, and 49 (45%) babies were exposed to bedaquiline in utero. Low birth weight was reported in more babies exposed to bedaquiline compared to babies not exposed (45% vs 26%; P = .034). In multivariate analyses, bedaquiline and levofloxacin, drugs often used in combination, were both independently associated with increased risk of low birth weight. Of the 86 children evaluated at 12 months, 72 (84%) had favorable outcomes; 88% of babies exposed to bedaquiline were thriving and developing normally compared to 82% of the babies not exposed. CONCLUSIONS: MDR/RR-tuberculosis treatment outcomes among pregnant women were comparable to nonpregnant women. Although more babies exposed to bedaquiline were of low birth weight, over 80% had gained weight and were developing normally at 1 year.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Loveday M, Hughes J, Sunkari B, et al. Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa. Clin Infect Dis. 2021. PMID: 32141495. doi:10.1093/cid/ciaa189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。